These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414 [TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289 [TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment. Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338 [TBL] [Abstract][Full Text] [Related]
10. Letermovir prophylaxis reduced cytomegalovirus reactivation and resistance post umbilical cord blood transplantation. Yan B; Sun G; Wu Y; Wu W; Song K; Cheng Y; Huang A; Pan T; Tang B; Zhu X Br J Haematol; 2024 Jun; 204(6):2378-2389. PubMed ID: 38581290 [TBL] [Abstract][Full Text] [Related]
11. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994 [TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection in seropositive unrelated cord blood recipients: a study of 349 Korean patients. Park M; Lee YH; Lee SH; Yoo KH; Sung KW; Koo HH; Lee JW; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Chung NG; Cho B; Kim HK; Koh KN; Im HJ; Seo JJ; Baek HJ; Kook H; Hwang TJ; Lee JM; Hah JO; Lim YJ; Park JE; Lyu CJ; Lim YT; Chong SY; Oh D; Ann Hematol; 2015 Mar; 94(3):481-9. PubMed ID: 25417830 [TBL] [Abstract][Full Text] [Related]
13. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients. Kamar N; Mengelle C; Esposito L; Guitard J; Mehrenberger M; Lavayssière L; Ribes D; Cointault O; Durand D; Izopet J; Rostaing L J Med Virol; 2008 Jun; 80(6):1012-7. PubMed ID: 18428146 [TBL] [Abstract][Full Text] [Related]
14. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Takami A; Mochizuki K; Asakura H; Yamazaki H; Okumura H; Nakao S Haematologica; 2005 Sep; 90(9):1290-2. PubMed ID: 16154862 [TBL] [Abstract][Full Text] [Related]
15. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients. McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799 [TBL] [Abstract][Full Text] [Related]
16. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758 [TBL] [Abstract][Full Text] [Related]
17. Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study. Chitasombat MN; Watcharananan SP F1000Res; 2018; 7():1568. PubMed ID: 30473779 [No Abstract] [Full Text] [Related]
18. Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial. Cowley NJ; Owen A; Shiels SC; Millar J; Woolley R; Ives N; Osman H; Moss P; Bion JF JAMA Intern Med; 2017 Jun; 177(6):774-783. PubMed ID: 28437539 [TBL] [Abstract][Full Text] [Related]
19. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients. Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981 [TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers. Frantzeskaki FG; Karampi ES; Kottaridi C; Alepaki M; Routsi C; Tzanela M; Vassiliadi DA; Douka E; Tsaousi S; Gennimata V; Ilias I; Nikitas N; Armaganidis A; Karakitsos P; Papaevangelou V; Dimopoulou I J Crit Care; 2015 Apr; 30(2):276-81. PubMed ID: 25457114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]